CN101716178B - Antitumor medicament - Google Patents
Antitumor medicament Download PDFInfo
- Publication number
- CN101716178B CN101716178B CN2009103103827A CN200910310382A CN101716178B CN 101716178 B CN101716178 B CN 101716178B CN 2009103103827 A CN2009103103827 A CN 2009103103827A CN 200910310382 A CN200910310382 A CN 200910310382A CN 101716178 B CN101716178 B CN 101716178B
- Authority
- CN
- China
- Prior art keywords
- compound
- pyridine
- activity
- compounds
- medicament
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 0 CCC(c1c(*)c(*)c(*)c(*)c1C(CC*)=O)N=O Chemical compound CCC(c1c(*)c(*)c(*)c(*)c1C(CC*)=O)N=O 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses an antitumor medicament in the technical field of medicine chemical industry, which refers to 6-substituted-5, 6-dihydropyrrol [3, 4-d] pyridine-7-ketone (IV), having the following structural general formulas. The medicament is a compound with higher protein kinase inhibiting activity, has a simple preparation method and convenient raw material sources, is easy to realize industrialization and can satisfy the requirement for preparing the medicament for clinically treating cancers.
Description
The present invention is by number of patent application: 200810033294.2, and name of patent application: be used for anti-tumor drug, the applicant: Shanghai Communications University, the applying date: the patent on January 31st, 2008 is divided an application.
Technical field
The present invention relates to a kind of chemical compound of medical chemistry field of engineering technology, specifically is a kind of anti-tumor drug that is used for.
Background technology
Thalidomide (thalidomide) is a kind of glutamate derivatives, and following six biological activitys are arranged: (1) anti-cachexia effect.(2) antineoplastic starts effect.(3) effect of angiogenesis inhibitor promptly suppresses the vascular endothelial growth effect.(4) anti-cell etching effect.(5) antiviral effect.(6) hypoglycemic effect.Thalidomide is a kind of medicine of many targeting, and it is mould that it can act on amino peptide mould (PSA) of endotheliocyte growth factor (PD-ECGF), the mould IV of dipeptides peptide (DPP-IV), puromycin and alpha-glucosaccharase that mould (the TP)/platelet of androgen receptor (AR), dT phosphorylation derives.Thalidomide is used for the treatment of multiple myeloma in December, 2003 by Australia's approval.But Thalidomide has side effect such as constipation, erythra, peripheral neuropathy, teratogenesis.Many national major companies are developing thalidomide analogs, to strengthen its anti-tumor activity, reduce its toxic and side effects.
Find through literature search prior art, Bull.Chem.Soc.Jpn.1989,62, publish on 1205 " Magnesium Ion Assisted Highly Regio-and Chemoselective Reduction of5H-Pyrrolo[3; 4-b] pyridine-5; 7 (6H)-diones with Sodium Borohydride.A ConvenientSynthesis of 6; 7-Dihydro-7-hydroxy-5H-pyrrolo[3; 4-b] pyridine-5-ones. " (assist sodium borohydride position and chemical selective reduction 5H-pyrrolo-[3 with magnesium ion, 4-b] pyridine-5,7 (6H)-diketone: a kind of easy synthetic 6,7-dihydro-7 hydroxyls-5H-pyrrolo-[3,4-b] pyridine-5-ketone), mention in this article with sodium borohydride and the adjacent dicarboximide of magnesium perchlorate selective reduction and obtain 7-position hydroxyl lactim chemical compound, do not provide chemical compound 5-hydroxyl-6-ethyl-5 that the present invention mentions in the literary composition, 6-pyrrolin also [3,4-b] pyridin-7-one, 5-hydroxyl-6-isopropyl-5, the spectral data of 6-dihydro-pyrrolo-[3,4-b] pyridin-7-one.
Synth.Commun.2006,36, " the Efficient Synthesis of Ary Hydroxylactamsby Reducing Imides with Activated Zinc Dust. " of publication (by the effective synthesizing fragrant hydroxyl of activated zinc powder reduction imidodicarbonic diamide lactim) on 435, mention in this article with the adjacent dicarboximide of activated zinc powder selective reduction and obtain 7-position hydroxyl lactim chemical compound, do not provide chemical compound 3-(the 5-hydroxyl-7-ketone-5 that the present invention mentions in the literary composition, 7-dihydro-pyrrolo-[3,4-b] pyridine)-piperidines-2, the spectral data of 6-diketone.Because Thalidomide has serious toxic and side effects, and the poor solubility of this medicine, its application is restricted.Therefore the antitumor drug of developing efficient, low toxic and side effects has important practical significance.
Summary of the invention
The objective of the invention is at the deficiencies in the prior art, provide a class to be used for anti-tumor drug, making it solve in prior art cancer therapy drug has strong toxicity, and chemical sproof technical problem.
The present invention is achieved by the following technical solutions:
The anti-tumor drug that is used for involved in the present invention comprises three series, four big compounds promptly: (1) 2-replacement-3-hydroxyl-2,3-dihydro-iso-indoles-1-ketone I, (2) 6-replacement-5-hydroxyl-5,6-pyrrolin also [3,4-b] pyridin-7-one II, (3) 6-replaces-5, and the 6-pyrrolin is [3,4-b] pyridin-7-one III also, (4) 6-replaces-5, the 6-pyrrolin is [3,4-d] pyrimidin-7-ones IV also, and its general structure is as follows respectively:
The Compound I general structure:
Wherein: R
1, R
2, R
3And R
4Base, expression H, alkyl, alkoxyl, ester group, aryl, aryloxy group, benzyl, CF
3, OH, N
3, NH
2, NO
2, CN, NHCOR
1', NR
2' R
3', F, Cl, a kind of among the Br; N-R
5Expression N-H, the N-alkyl, the N-aryl, the N-benzyl, the N-heterocyclic compound, a kind of in aminoacid and the amino-acid ester thereof, preferred chemical compound sees Table-1.
Compound I I general structure is as follows:
Wherein: R
1, R
2, R
3Base, expression H, alkyl, alkoxyl, ester group, aryl, aryloxy group, benzyl, CF
3, OH, N
3, NH
2, NO
2, CN, NHCOR
1', NR
2' R
3', F, Cl, a kind of among the Br; N-R
4Expression N-H, the N-alkyl, the N-aryl, the N-benzyl, the N-heterocyclic compound, a kind of in aminoacid and the amino-acid ester thereof, preferred chemical compound sees Table-2.
The compound III general structure is as follows:
Wherein: R
1, R
2, R
3Base, expression H, alkyl, alkoxyl, ester group, aryl, aryloxy group, benzyl, CF
3, OH, N
3, NH
2, NO
2, CN, NHCOR
1', NR
2' R
3', F, Cl, a kind of among the Br; N-R
4Expression N-H, the N-alkyl, the N-aryl, the N-benzyl, the N-heterocyclic compound, a kind of in aminoacid and the amino-acid ester thereof, preferred chemical compound sees Table-3.
The compound IV general structure is as follows:
Wherein: R
1, R
2Base, expression H, alkyl, alkoxyl, ester group, aryl, aryloxy group, benzyl, CF
3, OH, N
3, NH
2, NO
2, CN, NHCOR
1', NR
2' R
3', F, Cl, a kind of among the Br; N-R
4Expression N-H, the N-alkyl, the N-aryl, the N-benzyl, the N-heterocyclic compound, a kind of in aminoacid and the amino-acid ester thereof, preferred chemical compound sees Table-4.
General structure is that the preparation method of the chemical compound of I is to be raw material with the o-phthalaldehyde(OPA), obtains 2-with the organic amine reaction and replaces-2,3-dihydro-iso-indoles-1-ketone.Then intermediate 2-is replaced-2,3-dihydro-iso-indoles-1-ketone and N-bromo-succinimide (NBS)/benzoyl peroxide (BPO) refluxes in benzene, and separation, purification just obtain target compound I.
General structure is that the preparation method of the chemical compound of II, III is with 2-cyano group-3-methyl-pyridine raw material hydrolysis in the aqueous solution of sodium hydroxide, transfers ph=2-3 with hydrochloric acid, obtains intermediate 3-methyl-2-pyridine carboxylic acid.Then, with sulphuric acid catalysis, obtain 3-methyl-2-pyridine carboxylic acid methyl ester with the methanol reaction.Again 3-methyl-2-pyridine carboxylic acid methyl ester and N-bromo-succinimide (NBS)/azo isobutyl cyanogen (AIBN) reaction are obtained intermediate 3-bromomethyl-2-pyridine carboxylic acid methyl ester.And then the reaction of 3-bromomethyl-2-pyridine carboxylic acid methyl ester and corresponding organic amine obtained compound III.Again compound III and N-bromo-succinimide (NBS)/azo isobutyl cyanogen (AIBN) reaction are obtained Compound I I.
General structure is that the preparation method of the chemical compound of IV is to be raw material with 4-chloro-ethyl acetoacetate, obtain compound 4-chloro-2-ethoxy ethylene base-3-carbonyl-ethyl n-butyrate. with the reaction of triethyl orthoformate and acetic anhydride, subsequently with formamidine acetate react 4-chloromethyl-5-pyrimidinecarboxylic acid ethyl ester.Again 4-chloromethyl-5-pyrimidinecarboxylic acid ethyl ester and corresponding organic amine reaction are obtained corresponding compounds IV.
The present invention also provides the application of above-mentioned this compounds in antitumor drug, promptly Compound I, II, III, IV are carried out bioactivity screening to vascular endothelial cell (ECV-304), human lung carcinoma cell (A549), human T cell leukemia cell (CEM), people's promyelocytic leukemia cell cell strains such as (HL-60) according to the method for existing drug screening, its pharmacology result sees Table-5 respectively, table-6, table-7, table-8.
The preparation method of Compound I I provided by the invention is compared with the method that above-mentioned document is mentioned, and the method that above-mentioned document is mentioned is difficult to obtain 5-hydroxyl-6-and replaces-5,6-dihydro-pyrrolo-[3,4-b] this compounds of pyridin-7-one.The chemical compound that the present invention mentioned suppress vascular endothelial cell (ECV-304) and anti-pulmonary carcinoma (A549), (CEM, HL-60) remarkable enhancing is compared in the aspect to the leukemia cell with Thalidomide.
The specific embodiment
Below embodiments of the invention are elaborated: present embodiment is being to implement under the prerequisite with the technical solution of the present invention, provided detailed embodiment and concrete operating process, but protection scope of the present invention is not limited to following embodiment.
Embodiment 1
2-methyl propionate base-3-hydroxyl-2,3-dihydro-iso-indoles-1-ketone I-2
With 438mg (2mmol) 2-methyl propionate base-2,3-dihydro-iso-indoles-1-ketone V-2 and 442mg (2mmol) trifluoroacetic acid silver are dissolved in 10ml CHCl
3, drip 320mg (2mmol) Br in-20 ℃
2(be dissolved in 10ml CHCl
3), dropwise about 1 hour.Stir 3h then under room temperature, filter, filtrate decompression is distilled to dried, purify colourless oil liquid 360mg, yield 76.6%.Its analyzing test data sees Table-1.
Embodiment 2
2-dimethyl succinate base-3-hydroxyl-2,3-dihydro-iso-indoles-1-ketone I-3
With 277mg (1mmol) 2-dimethyl succinate base-2,3-dihydro-iso-indoles-1-ketone V-3 and 48mg (0.2mmol) benzoyl peroxide are dissolved in the acetonitrile of 15ml, slowly add 358mg (2mmol) NBS under room temperature.0 ℃ of following 5h then, cooling is filtered, filtrate decompression is distilled to dried, purify colourless oil liquid 206mg, yield 88.74%.Its analyzing test data sees Table-1.
Embodiment 3
5-hydroxyl-6-ethyl-5,6-pyrrolin be [3,4-b] pyridin-7-one II-1 also
6-ethyl-5,6-pyrrolin be [3,4-b] pyridin-7-one III-1 (0.243g also, 1.5mmol), N-bromo-succinimide (NBS) (0.333g, 1.875mmol), azo-bis-isobutyl cyanide (AIBN) (0.031g, 0.1875mmol), anhydrous acetonitrile 20ml is in two mouthfuls of bottles of 50ml, stir, backflow 2-4h after reaction finishes, handles according to a conventional method and purifies, get colorless solid 0.112 gram, yield 42%.Its analyzing test data sees Table-2
Embodiment 4
5-hydroxyl-6-(3-bromo-4-methoxyl group) phenyl-5, the 6-pyrrolin is [3,4-b] pyridin-7-one II-15 also
6-(4-methoxyl group) phenyl-5,6-dihydro-pyrrolo-[3,4-b] pyridin-7-one III-15 (0.36g, 1.5mmol), N-bromo-succinimide (NBS) (1.068g, 6.0mmol), azo-bis-isobutyl cyanide (AIBN) (0.098g, 0.60mmol), anhydrous acetonitrile 50ml is in the reaction bulb of 100ml, stir, reflux, follow the tracks of reaction process with tlc analysis plate (TLC), the raw material fundamental reaction finishes to get final product cessation reaction, vacuum rotary steam is removed acetonitrile then, column chromatography is purified, with dichloromethane: methanol=80: 1 eluting, colorless solid II-15,0.165g, yield 33%, colorless solid III-16,0.306g yield 64%.Its analyzing test data sees Table-2.
Embodiment 5
3-(5-hydroxyl-7-ketone-5,7-pyrrolin be [3,4-b] pyridine also)-piperidines-2,6-diketone II-16
3-(7-carbonyl-5,7-dihydro-pyrrolo-[3,4-b] pyridine-) piperidines-2,6-diketone III-19 (0.245g, 1.0mmol), N-bromo-succinimide (NBS) (0.534g, 3.0mmol), azo-bis-isobutyl cyanide (AIBN) (0.050g, 0.3mmol), anhydrous acetonitrile 60ml stirs in the reaction bulb of 100ml, refluxes, follow the tracks of reaction process with tlc analysis plate (TLC), the raw material fundamental reaction finishes to get final product cessation reaction, and vacuum rotary steam is removed acetonitrile then, and column chromatography is purified.With dichloromethane: methanol=80: 1 and dichloromethane: methanol=50: 1 gradient elutions.Get colorless solid 3-(5-hydroxyl-7-ketone-5,7-pyrrolin also [3,4-b] pyridine)-piperidines-2,6-diketone II-16,0.029g yield 11%, colorless solid 3-[5-(2,5-dicarbapentaborane-pyrrolidine)-5-hydroxyl-7-ketone-5, the 7-pyrrolin is [3,4-b] pyridine also)]-piperidines-2,6-diketone II-20,0.266g yield 74.3%.Its analyzing test data sees Table-2.
The physical data of table-1 I analog derivative
The physical data of table-2 II analog derivatives
The physical data (continuing) of table-2 II analog derivatives
1HNMR (300MHz, DMSO-d
6): δ 11.1 (1H, s, OH), 11.0 (1H, br, NH), 9.02-9.04 (1H, d, d, J=1.5,5.1Hz, Py-2), 8.36-8.39 (1H, d, d, J=1.5,7.8Hz, Py-4), 7.82-7.871 (1H, d, d, J=5.1,7.8Hz, Py-3), 5.19-5.28 (1H, d, d, J=5.7,7.5Hz, NCHCO), 2.85-2.94 (2H, m, COCH
2), 2.48-2.63 (5H, m, COCH
2CH
2CO, CH
2CH
2CO), 2.04-2.10 (1H, m, CH
2CH
2CO).
13CNMR (75MHz, DMSO-d
6): δ 180.0 (CO), 180.0 (CO), 173.4 (C=O), 170.3 (C=O), 166.1 (C=O), 156.0 (Py-2), 151.7 (Py-6), 132.4 (Py-5), 129.0 (Py-4), 127.6 (Py-3), 88.1 (NCHOH), 49.7 (NCHCO), 31.4 (COCH
2), 30.1 (COCH
2CH
2CO), 30.1 (COCH
2CH
2CO), 22.5 (COCH
2CH
2) .LC-MS:(ESI) (M+2)
+360.2. yield 74.3%, colorless solid, mp:119-121 ℃.
The physical data of table-3 III analog derivatives
The physical data of table-4 IV analog derivatives:
The The pharmacological results of table-5 I analog derivatives:
The The pharmacological results of table-6 II analog derivatives:
The The pharmacological results of table-7 III analog derivatives:
The The pharmacological results of table-8 IV analog derivatives:
The pharmacological results is summed up:
With thalidomide is tester, I, II, III, IV compounds are carried out the screening of external human umbilical vein endothelial cell (ECV-304), human lung carcinoma cell (A549), human T cell leukemia cell (CEM), four groups of cells of people's promyelocytic leukemia cell (HL-60), the results are shown in Table-5, table-6, table-7 and table-8.The activity of individual compound and thalidomide are suitable in the I compounds, but the activity of majority of compounds all is better than thalidomide.(as II-9,10) is suitable with thalidomide for the activity of individual compound in the II compounds, but majority of compounds shows the activity of very strong inhibition tumor and inhibition vascular endothelial cell.From the group of 6 links, find that aromatic rings, aliphatic chain significantly strengthen than the active of amino acid esters, wherein II-4,5,6,13,14,15 has the effect of the very strong above-mentioned cell of inhibition, along with the increase of carbochain, its active significantly strengthen (C＞4).In all chemical compounds of II class, the activity of the inhibition human umbilical vein endothelial cell (ECV-304) of II-15 is the strongest, and this chemical compound is all more weak to other three groups of cell inhibiting.This illustrates that this chemical compound has the proliferation activity that optionally suppresses vascular endothelial cell (ECV-304).This illustrates that also suitably introducing halogen atom on phenyl ring can increase its biological activity.The activity of individual compound and thalidomide are suitable in the III compounds, but the activity of majority of compounds will significantly be better than thalidomide.Its rule is similar to the II compounds, and aromatic rings, aliphatic chain significantly strengthen than the active of amino acid esters in the group of 6 links.In aliphatic chain, also be increase along with carbochain, all significantly enhancings of activity that it suppresses the activity of human umbilical vein endothelial cell (ECV-304) and suppresses tumor.In aromatic rings, halogen atom also is the biological activity that has obviously strengthened chemical compound.In all chemical compounds of III class, III-5,16 has the activity of very strong inhibition human umbilical vein endothelial cell (ECV-304) and suppresses the activity of tumor.The activity of majority of compounds and thalidomide are suitable in the IV compounds, but compound IV-the 5th suppresses vascular endothelial cell (ECV-304) and human lung carcinoma cell (A549), human T cell leukemia cell (CEM), the strongest chemical compound of people's promyelocytic leukemia cell (HL-60) in all chemical compounds of this class.Proved that again the aliphatic chain of long carbochain can significantly strengthen the activity of chemical compound.
Claims (1)
1. one kind is used for anti-tumor drug, it is characterized in that, comprising: 6-replaces-5,6-dihydro-pyrrolo-[3,4-d] pyrimidin-7-ones (IV), and its general structure is as follows:
Wherein: R
1, R
2Be H, R
3Be respectively as follows:
(1)H
(2)CH
2CH
2CH
3 (6)CH
2(CH
2)
2OCH
3
(3)CH
3CHCH
3 (7)CH
2COOCH
3。
(4)CH
2(CH
2)
2CH
3
(5)CH
2(CH
2)
4CH
3
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2009103103827A CN101716178B (en) | 2008-01-31 | 2008-01-31 | Antitumor medicament |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2009103103827A CN101716178B (en) | 2008-01-31 | 2008-01-31 | Antitumor medicament |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2008100332942A Division CN101225070B (en) | 2008-01-31 | 2008-01-31 | Antineoplastic medicament |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101716178A CN101716178A (en) | 2010-06-02 |
| CN101716178B true CN101716178B (en) | 2011-06-01 |
Family
ID=42430875
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2009103103827A Expired - Fee Related CN101716178B (en) | 2008-01-31 | 2008-01-31 | Antitumor medicament |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101716178B (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1405166A (en) * | 2002-10-28 | 2003-03-26 | 中国科学院长春应用化学研究所 | Thalidomide and its derivatives preparation method |
-
2008
- 2008-01-31 CN CN2009103103827A patent/CN101716178B/en not_active Expired - Fee Related
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1405166A (en) * | 2002-10-28 | 2003-03-26 | 中国科学院长春应用化学研究所 | Thalidomide and its derivatives preparation method |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101716178A (en) | 2010-06-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101225070B (en) | Antineoplastic medicament | |
| Ohashi et al. | Discovery of the investigational drug TAK-441, a pyrrolo [3, 2-c] pyridine derivative, as a highly potent and orally active hedgehog signaling inhibitor: Modification of the core skeleton for improved solubility | |
| Cao et al. | Design, synthesis and in vitro and in vivo antitumor activities of novel β-carboline derivatives | |
| JP5795630B2 (en) | Cyclopropyldicarboxamide and analogs exhibiting anticancer and antiproliferative activity | |
| CN107382973B (en) | 5-aminopyrazole carboxamide derivatives as BTK inhibitors, process for their preparation and pharmaceutical compositions containing them | |
| JP4105592B2 (en) | Huperzine A derivatives, their preparation and their use | |
| EP3904351A1 (en) | Fak inhibitor and drug combination thereof | |
| JP2020512399A (en) | IDO inhibiting compounds, their preparation and their use | |
| KR20200141041A (en) | Macrocyclic compounds as TRK kinase inhibitors | |
| CA2878332A1 (en) | Protein kinase inhibitors | |
| KR20150095905A (en) | Indole carboxamide derivatives as p2x7 receptor antagonists | |
| AU2006343604A1 (en) | 3,4-disubstituted coumarin and quinolone compounds | |
| JP2023509001A (en) | Compounds with KHK inhibitory effect | |
| TWI694824B (en) | A formamide compound, a process for its preparation and use of the same | |
| WO2017088755A1 (en) | Aminopyrimidine heterocyclic compound with adenosine receptor antagonistic activity | |
| CN110240598B (en) | Process for preparing carboxamide derivatives and intermediate compounds thereof | |
| JP2022539752A (en) | Heterocycloalkyl compounds as CCR2/CCR5 antagonists | |
| CN101716178B (en) | Antitumor medicament | |
| CN101703507B (en) | Antineoplastic medicament | |
| CN107573336B (en) | Benzoheterocycle-formamide-pyridone derivative and preparation method and application thereof | |
| CN111848572B (en) | Amide compound and preparation method and application thereof | |
| TWI794576B (en) | A class of fluorine-substituted benzothiophene compounds and their pharmaceutical compositions and applications | |
| CN115466257A (en) | Compound with TYK2 inhibitory activity, pharmaceutical composition containing same, and application thereof | |
| Guo et al. | Synthesis and antitumor activities of novel bivalent 1-Heterocyclic-β-carbolines linked by alkylamino spacer | |
| CN115572247B (en) | Vitamin K 3 Derivatives and medical use thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20110601 Termination date: 20150131 |
|
| EXPY | Termination of patent right or utility model |